Log in
NASDAQ:ZYNE

Zynerba Pharmaceuticals Stock Forecast, Price & News

$3.70
-0.10 (-2.63 %)
(As of 09/18/2020 09:43 PM ET)
Add
Compare
Today's Range
$3.60
Now: $3.70
$3.78
50-Day Range
$3.51
MA: $3.80
$4.30
52-Week Range
$2.55
Now: $3.70
$8.83
Volume702,800 shs
Average Volume1.02 million shs
Market Capitalization$108.24 million
P/E RatioN/A
Dividend YieldN/A
Beta2.97
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.
Read More
Zynerba Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZYNE
CUSIPN/A
Phone484-581-7505

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90,000.00
Book Value$3.26 per share

Profitability

Net Income$-32,940,000.00

Miscellaneous

Employees25
Market Cap$108.24 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$3.70
-0.10 (-2.63 %)
(As of 09/18/2020 09:43 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYNE News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYNE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zynerba Pharmaceuticals (NASDAQ:ZYNE) Frequently Asked Questions

How has Zynerba Pharmaceuticals' stock been impacted by Coronavirus?

Zynerba Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZYNE shares have decreased by 4.9% and is now trading at $3.70.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Zynerba Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zynerba Pharmaceuticals
.

When is Zynerba Pharmaceuticals' next earnings date?

Zynerba Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Zynerba Pharmaceuticals
.

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) posted its quarterly earnings data on Monday, August, 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.33.
View Zynerba Pharmaceuticals' earnings history
.

What price target have analysts set for ZYNE?

6 analysts have issued 12-month price objectives for Zynerba Pharmaceuticals' stock. Their forecasts range from $8.00 to $26.00. On average, they anticipate Zynerba Pharmaceuticals' stock price to reach $14.33 in the next twelve months. This suggests a possible upside of 287.4% from the stock's current price.
View analysts' price targets for Zynerba Pharmaceuticals
.

Are investors shorting Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals saw a drop in short interest in August. As of August 31st, there was short interest totaling 4,330,000 shares, a drop of 15.4% from the August 15th total of 5,120,000 shares. Based on an average daily volume of 1,460,000 shares, the days-to-cover ratio is currently 3.0 days.
View Zynerba Pharmaceuticals' Short Interest
.

Who are some of Zynerba Pharmaceuticals' key competitors?

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Canopy Growth (CGC), Cara Therapeutics (CARA), GW Pharmaceuticals PLC- (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Innovative Industrial Properties (IIPR) and Shopify (SHOP).

Who are Zynerba Pharmaceuticals' key executives?

Zynerba Pharmaceuticals' management team includes the following people:
  • Mr. Armando Anido M.B.A., MBA, Chairman & CEO (Age 61)
  • Ms. Terri B. Sebree, Pres (Age 61)
  • Mr. James E. Fickenscher, CFO, VP of Corp. Devel. & Treasurer (Age 55)
  • Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 50)
  • Ms. Suzanne M. Hanlon, Sec., VP & Gen. Counsel (Age 62)

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering (IPO) on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

What is Zynerba Pharmaceuticals' stock symbol?

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Zeke Capital Advisors LLC (1.77%), AdvisorShares Investments LLC (1.53%), Jane Street Group LLC (0.47%), Bridgeway Capital Management Inc. (0.41%), Goldman Sachs Group Inc. (0.24%) and Algert Global LLC (0.16%).
View institutional ownership trends for Zynerba Pharmaceuticals
.

Which major investors are selling Zynerba Pharmaceuticals stock?

ZYNE stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp.
View insider buying and selling activity for Zynerba Pharmaceuticals
.

Which major investors are buying Zynerba Pharmaceuticals stock?

ZYNE stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Bridgeway Capital Management Inc., Zeke Capital Advisors LLC, Goldman Sachs Group Inc., AdvisorShares Investments LLC, Nisa Investment Advisors LLC, PDT Partners LLC, and Engineers Gate Manager LP.
View insider buying and selling activity for Zynerba Pharmaceuticals
.

How do I buy shares of Zynerba Pharmaceuticals?

Shares of ZYNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zynerba Pharmaceuticals' stock price today?

One share of ZYNE stock can currently be purchased for approximately $3.70.

How big of a company is Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals has a market capitalization of $108.24 million and generates $90,000.00 in revenue each year. The company earns $-32,940,000.00 in net income (profit) each year or ($1.50) on an earnings per share basis. Zynerba Pharmaceuticals employs 25 workers across the globe.

What is Zynerba Pharmaceuticals' official website?

The official website for Zynerba Pharmaceuticals is www.zynerba.com.

How can I contact Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals' mailing address is 80 W. LANCASTER AVENUE SUITE 300, DEVON PA, 19333. The company can be reached via phone at 484-581-7505 or via email at [email protected]

This page was last updated on 9/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.